Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...

Novo Nordisk (NVO) was slammed by a U.K. trade group for violating voluntary codes and discrediting the pharmaceutical industry over a failure ...

Here are some of the major companies whose stocks moved on the week’s news.

Novo Nordisk was slammed by a U.K. trade group for not disclosing payments to health and patient groups, according to a draft ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

The advisory is intended to prevent delays in identifying human cases of avian influenza A (H5N1) viruses amid high levels of seasonal influenza Like Ebola, the Marburg virus originates in fruit ...

Vanitha SV, global lead for modular content and insights, commercial excellence and operations at Novo Nordisk ... they have available to them.” DCB Health’s director of customer solutions ...

Other recent partnerships in the molecular glue degrader category include Takeda's recent $1 billion-plus link-up with Degron Therapeutics, a $1.46 billion deal between Novo Nordisk and Neomorph ...